Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin Salvage Treatment in Relapsed/Refractory Aggressive B-cell Lymphoma
NCT00902525Phase 2Terminated
- Sponsor
- GIMEMA
- Start
- Jan 2008
- Primary completion
- Jan 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in diffuse large B-cell lymphoma (DLBCL), sponsored by GIMEMA. Primary endpoints: Efficacy, Safety and 1 more. Started Jan 2008; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00902525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902525.